Non-steroidal Anti-inflammatory Drugs Market Size, Share & Trends Analysis Report By Disease Indication (Arthritis, Migraine, Ophthalmic Diseases), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030
This report can be delivered to the clients within 3 Business Days
Non-steroidal Anti-inflammatory Drugs Market Growth & Trends
The global non-steroidal anti-inflammatory drugs market is expected to reach USD 31.29 billion by 2030, expanding at a CAGR of 5.36% during the forecast period, according to a new report by Grand View Research, Inc. Nonsteroidal anti-inflammatory drugs are drugs that are primarily used to relieve inflammation and pain, as well as to lower elevated body temperature. The high prescription rate of non-steroidal anti-inflammatory drugs (NSAIDs) for relief of symptoms of painful periods, headaches, fever, arthritis, sprains, strains, and other types of chronic pain is expected to drive the market during the forecast period.
The non-steroidal anti-inflammatory drugs market is expected to witness growth opportunities owing to factors such as the rising prevalence of targeted diseases and chronic pain across the globe, coupled with the high prevalence of these diseases in the geriatric population. Moreover, increasing demand for OTC NSAIDs and the rising adoption of NSAIDs for headaches, migraines, and menstrual pain are also expected to boost the growth during the forecast period.
Moreover, the increasing prevalence of arthritis and other pain-related disorders is also expected to support the growth. For instance, the prevalence of osteoarthritis is higher in the UK, France, and Germany compared to other countries in the Europe region. The prevalence of arthritis is seen to be lower in people who are often engaged in physical activities, and its prevalence rises with age. Thus, the rising prevalence of arthritis is also expected to cater to the growth during the forecast period.
Key market players are adopting strategic initiatives such as geographical expansion and the introduction of combination non-steroidal anti-inflammatory drugs to increase their market share across the globe. For instance, Alkem Labs and Dr. Reddy’s Laboratories Ltd have launched their non-steroidal anti-inflammatory drugs in the U.S. Moreover, increasing approval of OTC drugs for pain management and other inflammatory diseases is expected to drive growth during the forecast period. Thus, owing to the various strategies adopted by key players, the market is likely to boost its growth.
Governments in various regions are undertaking favorable initiatives to reduce the burden of migraine, arthritis, and other diseases in their countries. For instance, the National Institutes of Health has initiated HEAL to accelerate research activities to improve the management of pain and inflammatory diseases. Moreover, the Patient-Centered Outcomes Research Institute has undertaken initiatives to introduce non-opioid treatment options for pain. Such initiatives are expected to increase growth during the forecast period.
Non-steroidal Anti-inflammatory Drugs Market Report Highlights
Non-steroidal Anti-inflammatory Drugs Market Growth & Trends
The global non-steroidal anti-inflammatory drugs market is expected to reach USD 31.29 billion by 2030, expanding at a CAGR of 5.36% during the forecast period, according to a new report by Grand View Research, Inc. Nonsteroidal anti-inflammatory drugs are drugs that are primarily used to relieve inflammation and pain, as well as to lower elevated body temperature. The high prescription rate of non-steroidal anti-inflammatory drugs (NSAIDs) for relief of symptoms of painful periods, headaches, fever, arthritis, sprains, strains, and other types of chronic pain is expected to drive the market during the forecast period.
The non-steroidal anti-inflammatory drugs market is expected to witness growth opportunities owing to factors such as the rising prevalence of targeted diseases and chronic pain across the globe, coupled with the high prevalence of these diseases in the geriatric population. Moreover, increasing demand for OTC NSAIDs and the rising adoption of NSAIDs for headaches, migraines, and menstrual pain are also expected to boost the growth during the forecast period.
Moreover, the increasing prevalence of arthritis and other pain-related disorders is also expected to support the growth. For instance, the prevalence of osteoarthritis is higher in the UK, France, and Germany compared to other countries in the Europe region. The prevalence of arthritis is seen to be lower in people who are often engaged in physical activities, and its prevalence rises with age. Thus, the rising prevalence of arthritis is also expected to cater to the growth during the forecast period.
Key market players are adopting strategic initiatives such as geographical expansion and the introduction of combination non-steroidal anti-inflammatory drugs to increase their market share across the globe. For instance, Alkem Labs and Dr. Reddy’s Laboratories Ltd have launched their non-steroidal anti-inflammatory drugs in the U.S. Moreover, increasing approval of OTC drugs for pain management and other inflammatory diseases is expected to drive growth during the forecast period. Thus, owing to the various strategies adopted by key players, the market is likely to boost its growth.
Governments in various regions are undertaking favorable initiatives to reduce the burden of migraine, arthritis, and other diseases in their countries. For instance, the National Institutes of Health has initiated HEAL to accelerate research activities to improve the management of pain and inflammatory diseases. Moreover, the Patient-Centered Outcomes Research Institute has undertaken initiatives to introduce non-opioid treatment options for pain. Such initiatives are expected to increase growth during the forecast period.
Non-steroidal Anti-inflammatory Drugs Market Report Highlights
- In 2021, the arthritis segment dominated the NSAIDs market owing to the higher prevalence of arthritis across the globe
- The retail pharmacy segment held the largest share and is anticipated to maintain its dominance during the forecast period
- Asia Pacific region is expected to witness the highest CAGR during the forecast period owing to factors such as the high prevalence of pain and related disorders, the high pool of patients, and a rising geriatric population across the region
- North America dominated the market in 2021 due to the higher prevalence of arthritis, the presence of leading market players, and increased research activities within the region
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market Segmentation and Scope
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: commodity flow approach
1.7 List of Secondary Sources
1.8 List of Abbreviations
1.9 Objectives
1.9.1 Objective
1.9.2 Objective
1.9.3 Objective
1.9.4 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Summary
CHAPTER 3 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET VARIABLES, TRENDS & SCOPE
3.1 Market Dynamics
3.1.1 Market Driver Analysis
3.1.1.1 Increasing Geriatric Population
3.1.1.2 Increasing Prevalence of Targeted Diseases
3.1.2 Market Restraint Analysis
3.1.2.1 Side-effects Associated with NSAIDs
3.2 Penetration and Growth Prospect Mapping
3.3 Business Environment Analysis Tools
3.3.1 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
3.3.2 Porter’s Five Forces Analysis
3.3.3 Industry Analysis - Ansoff Matrix
3.4 Pricing Analysis
3.5 Regulatory Scenario
CHAPTER 4 REGULATORY & POLITICAL FORCES
4.1 Recent Developments & Impact Analysis, by Key Market Participants
4.1.1 Heat map analysis
4.2 Company Categorization
4.2.1 Innovators
4.2.2 Market Leaders
4.3 Vendor Landscape
4.3.1 List of key distributors and channel partners
4.3.2 Key customers
4.3.3 Key company market share analysis, 2021
4.4 Public Companies
4.4.1 Company market position analysis
4.4.1.1 Market Differentiators
4.5 Private Companies
4.5.1 List of key emerging companies
4.6 Major Deals and Strategic Alliances Analysis
4.6.1 New Product Launch
4.6.2 Acquisitions
4.6.3 Expansion
4.6.4 Licensing and Partnerships
CHAPTER 5 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET - SEGMENT ANALYSIS, BY DISEASE INDICATION, 2018 - 2030 (USD MILLION)
5.1 Disease Indication Market Share Analysis, 2021 & 2030 (USD Million)
5.2 Segment Dashboard
5.3 Market Size & Forecasts and Trend Analysis, 2018 - 2030 (USD Million)
5.3.1 Arthritis
5.3.1.1 Arthritis market estimates and forecast, 2018 - 2030 (USD Million)
5.3.2 Migraine
5.3.2.1 Migraine market estimates and forecast, 2018 - 2030 (USD Million)
5.3.3 Ophthalmic Diseases
5.3.3.1 Ophthalmic diseases market estimates and forecast, 2018 - 2030 (USD Million)
5.3.4 Others
5.3.4.1 Other market estimates and forecast, 2018 - 2030 (USD Million)
CHAPTER 6 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET - SEGMENT ANALYSIS, BY ROUTE OF ADMINISTRATION, 2018 - 2030 (USD MILLION)
6.1 Route of Administration Market Share Analysis, 2021 & 2030 (USD Million)
6.2 Segment Dashboard
6.3 Market Size & Forecasts and Trend Analysis, 2018 to 2030 (USD Million)
6.3.1 Oral
6.3.1.1 Oral market estimates and forecast, 2018 - 2030 (USD Million)
6.3.2 Topical
6.3.2.1 Topical market estimates and forecast, 2018 - 2030 (USD Million)
6.3.3 Others
6.3.3.1 Other market estimates and forecast, 2018 - 2030 (USD Million)
CHAPTER 7 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET - SEGMENT ANALYSIS, BY DISTRIBUTION CHANNEL, 2018 - 2030 (USD MILLION)
7.1 Distribution Channel Market Share Analysis, 2021 & 2030 (USD Million)
7.2 Segment Dashboard
7.3 Market Size & Forecasts and Trend Analysis, 2018 to 2030 (USD Million)
7.3.1 Hospital Pharmacy
7.3.1.1 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
7.3.2 Retail Pharmacy
7.3.2.1 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
7.3.3 Online Pharmacy
7.3.3.1 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
CHAPTER 8 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET - SEGMENT ANALYSIS, BY REGION, 2018 - 2030 (USD MILLION)
8.1 Regional Market Share Analysis, 2021 & 2030 (USD Million)
8.2 Regional Market Dashboard
8.3 North America
8.3.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
8.3.2 U.S.
8.3.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
8.4 Canada
8.4.1. Canada market estimates and forecast, 2018 - 2030 (USD Million)
8.5 Europe
8.5.1 Europe market estimates and forecast, 2018 - 2030 (USD Million)
8.5.2 Germany
8.5.2.1 Germany market estimates and forecast, 2018 - 2030 (USD Million)
8.5.3 UK
8.5.3.1 UK market estimates and forecast, 2018 - 2030 (USD Million)
8.5.4 Spain
8.5.4.1 Spain market estimates and forecast, 2018 - 2030 (USD Million)
8.5.5 France
8.5.5.1 France market estimates and forecast, 2018 - 2030 (USD Million)
8.5.6 Italy
8.5.6.1 Italy market estimates and forecast, 2018 - 2030 (USD Million)
8.6 Asia Pacific
8.6.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
8.6.2 Japan
8.6.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Million)
8.6.3 China
8.6.3.1 China market estimates and forecast, 2018 - 2030 (USD Million)
8.6.4 India
8.6.4.1 India market estimates and forecast, 2018 - 2030 (USD Million)
8.6.5 South Korea
8.6.5.1 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
8.6.6 Australia
8.6.6.1 Australia market estimates and forecast, 2018 - 2030 (USD Million)
8.7 Latin America
8.7.1 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
8.7.2 Brazil
8.7.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
8.7.3 Mexico
8.7.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
8.7.4 Argentina
8.7.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
8.8 Middle East & Africa
8.8.1 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
8.8.2 South Africa
8.8.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
8.8.3 UAE
8.8.3.1 UAE market estimates and forecast, 2018 - 2030 (USD Million)
8.8.4 Saudi Arabia
8.8.4.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
CHAPTER 9 COMPETITIVE & VENDOR LANDSCAPE
9.1 Participant Categorization
9.1.1 Innovators
9.1.2 Market Leaders
9.2 Strategy Mapping
9.2.1 Key Strategies Chosen by Players in this Market Include:
9.2.1.1 Launch of new products
9.2.1.2 Acquisition
9.2.1.3 Expansion
9.2.1.4 Agreements, collaborations, partnerships
9.2.1.5 Others (realignment, divestment, market penetration):
9.3 Strategic Framework
9.3.1 Key Company Market Share Analysis, 2021
9.4 Company Profiles
9.4.1 Pfizer Inc.
9.4.1.1 Company overview
9.4.1.2 Financial performance
9.4.1.3 Product benchmarking
9.4.1.4 Strategic initiatives
9.4.2 Bayer AG
9.4.2.1 Company overview
9.4.2.2 Financial performance
9.4.2.3 Product benchmarking
9.4.2.4 Strategic initiatives
9.4.3 GSK plc
9.4.3.1 Company overview
9.4.3.2 Financial performance
9.4.3.3 Product benchmarking
9.4.3.4 Strategic initiatives
9.4.4 Dr. Reddy’s Laboratories Ltd
9.4.4.1 Company overview
9.4.4.2 Financial performance
9.4.4.3 Product pipeline
9.4.4.4 Strategic initiatives
9.4.5 Viatris Inc
9.4.5.1 Company overview
9.4.5.2 Financial performance
9.4.5.3 Product pipeline
9.4.5.4 Strategic initiatives
9.4.6 Teva Pharmaceutical Industries Ltd.
9.4.6.1 Company overview
9.4.6.2 Product benchmarking
9.4.6.3 Strategic initiatives
9.4.7 Johnson and Johnson Services, Inc.
9.4.7.1 Company overview
9.4.7.2 Financial performance
9.4.7.3 Product benchmarking
9.4.8 Merck & Co., Inc.
9.4.8.1 Company overview
9.4.8.2 Financial performance
9.4.8.3 Product benchmarking
9.4.8.4 Strategic initiatives
1.1 Market Segmentation and Scope
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: commodity flow approach
1.7 List of Secondary Sources
1.8 List of Abbreviations
1.9 Objectives
1.9.1 Objective
1.9.2 Objective
1.9.3 Objective
1.9.4 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Summary
CHAPTER 3 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET VARIABLES, TRENDS & SCOPE
3.1 Market Dynamics
3.1.1 Market Driver Analysis
3.1.1.1 Increasing Geriatric Population
3.1.1.2 Increasing Prevalence of Targeted Diseases
3.1.2 Market Restraint Analysis
3.1.2.1 Side-effects Associated with NSAIDs
3.2 Penetration and Growth Prospect Mapping
3.3 Business Environment Analysis Tools
3.3.1 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
3.3.2 Porter’s Five Forces Analysis
3.3.3 Industry Analysis - Ansoff Matrix
3.4 Pricing Analysis
3.5 Regulatory Scenario
CHAPTER 4 REGULATORY & POLITICAL FORCES
4.1 Recent Developments & Impact Analysis, by Key Market Participants
4.1.1 Heat map analysis
4.2 Company Categorization
4.2.1 Innovators
4.2.2 Market Leaders
4.3 Vendor Landscape
4.3.1 List of key distributors and channel partners
4.3.2 Key customers
4.3.3 Key company market share analysis, 2021
4.4 Public Companies
4.4.1 Company market position analysis
4.4.1.1 Market Differentiators
4.5 Private Companies
4.5.1 List of key emerging companies
4.6 Major Deals and Strategic Alliances Analysis
4.6.1 New Product Launch
4.6.2 Acquisitions
4.6.3 Expansion
4.6.4 Licensing and Partnerships
CHAPTER 5 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET - SEGMENT ANALYSIS, BY DISEASE INDICATION, 2018 - 2030 (USD MILLION)
5.1 Disease Indication Market Share Analysis, 2021 & 2030 (USD Million)
5.2 Segment Dashboard
5.3 Market Size & Forecasts and Trend Analysis, 2018 - 2030 (USD Million)
5.3.1 Arthritis
5.3.1.1 Arthritis market estimates and forecast, 2018 - 2030 (USD Million)
5.3.2 Migraine
5.3.2.1 Migraine market estimates and forecast, 2018 - 2030 (USD Million)
5.3.3 Ophthalmic Diseases
5.3.3.1 Ophthalmic diseases market estimates and forecast, 2018 - 2030 (USD Million)
5.3.4 Others
5.3.4.1 Other market estimates and forecast, 2018 - 2030 (USD Million)
CHAPTER 6 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET - SEGMENT ANALYSIS, BY ROUTE OF ADMINISTRATION, 2018 - 2030 (USD MILLION)
6.1 Route of Administration Market Share Analysis, 2021 & 2030 (USD Million)
6.2 Segment Dashboard
6.3 Market Size & Forecasts and Trend Analysis, 2018 to 2030 (USD Million)
6.3.1 Oral
6.3.1.1 Oral market estimates and forecast, 2018 - 2030 (USD Million)
6.3.2 Topical
6.3.2.1 Topical market estimates and forecast, 2018 - 2030 (USD Million)
6.3.3 Others
6.3.3.1 Other market estimates and forecast, 2018 - 2030 (USD Million)
CHAPTER 7 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET - SEGMENT ANALYSIS, BY DISTRIBUTION CHANNEL, 2018 - 2030 (USD MILLION)
7.1 Distribution Channel Market Share Analysis, 2021 & 2030 (USD Million)
7.2 Segment Dashboard
7.3 Market Size & Forecasts and Trend Analysis, 2018 to 2030 (USD Million)
7.3.1 Hospital Pharmacy
7.3.1.1 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
7.3.2 Retail Pharmacy
7.3.2.1 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
7.3.3 Online Pharmacy
7.3.3.1 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
CHAPTER 8 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET - SEGMENT ANALYSIS, BY REGION, 2018 - 2030 (USD MILLION)
8.1 Regional Market Share Analysis, 2021 & 2030 (USD Million)
8.2 Regional Market Dashboard
8.3 North America
8.3.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
8.3.2 U.S.
8.3.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
8.4 Canada
8.4.1. Canada market estimates and forecast, 2018 - 2030 (USD Million)
8.5 Europe
8.5.1 Europe market estimates and forecast, 2018 - 2030 (USD Million)
8.5.2 Germany
8.5.2.1 Germany market estimates and forecast, 2018 - 2030 (USD Million)
8.5.3 UK
8.5.3.1 UK market estimates and forecast, 2018 - 2030 (USD Million)
8.5.4 Spain
8.5.4.1 Spain market estimates and forecast, 2018 - 2030 (USD Million)
8.5.5 France
8.5.5.1 France market estimates and forecast, 2018 - 2030 (USD Million)
8.5.6 Italy
8.5.6.1 Italy market estimates and forecast, 2018 - 2030 (USD Million)
8.6 Asia Pacific
8.6.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
8.6.2 Japan
8.6.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Million)
8.6.3 China
8.6.3.1 China market estimates and forecast, 2018 - 2030 (USD Million)
8.6.4 India
8.6.4.1 India market estimates and forecast, 2018 - 2030 (USD Million)
8.6.5 South Korea
8.6.5.1 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
8.6.6 Australia
8.6.6.1 Australia market estimates and forecast, 2018 - 2030 (USD Million)
8.7 Latin America
8.7.1 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
8.7.2 Brazil
8.7.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
8.7.3 Mexico
8.7.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
8.7.4 Argentina
8.7.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
8.8 Middle East & Africa
8.8.1 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
8.8.2 South Africa
8.8.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
8.8.3 UAE
8.8.3.1 UAE market estimates and forecast, 2018 - 2030 (USD Million)
8.8.4 Saudi Arabia
8.8.4.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
CHAPTER 9 COMPETITIVE & VENDOR LANDSCAPE
9.1 Participant Categorization
9.1.1 Innovators
9.1.2 Market Leaders
9.2 Strategy Mapping
9.2.1 Key Strategies Chosen by Players in this Market Include:
9.2.1.1 Launch of new products
9.2.1.2 Acquisition
9.2.1.3 Expansion
9.2.1.4 Agreements, collaborations, partnerships
9.2.1.5 Others (realignment, divestment, market penetration):
9.3 Strategic Framework
9.3.1 Key Company Market Share Analysis, 2021
9.4 Company Profiles
9.4.1 Pfizer Inc.
9.4.1.1 Company overview
9.4.1.2 Financial performance
9.4.1.3 Product benchmarking
9.4.1.4 Strategic initiatives
9.4.2 Bayer AG
9.4.2.1 Company overview
9.4.2.2 Financial performance
9.4.2.3 Product benchmarking
9.4.2.4 Strategic initiatives
9.4.3 GSK plc
9.4.3.1 Company overview
9.4.3.2 Financial performance
9.4.3.3 Product benchmarking
9.4.3.4 Strategic initiatives
9.4.4 Dr. Reddy’s Laboratories Ltd
9.4.4.1 Company overview
9.4.4.2 Financial performance
9.4.4.3 Product pipeline
9.4.4.4 Strategic initiatives
9.4.5 Viatris Inc
9.4.5.1 Company overview
9.4.5.2 Financial performance
9.4.5.3 Product pipeline
9.4.5.4 Strategic initiatives
9.4.6 Teva Pharmaceutical Industries Ltd.
9.4.6.1 Company overview
9.4.6.2 Product benchmarking
9.4.6.3 Strategic initiatives
9.4.7 Johnson and Johnson Services, Inc.
9.4.7.1 Company overview
9.4.7.2 Financial performance
9.4.7.3 Product benchmarking
9.4.8 Merck & Co., Inc.
9.4.8.1 Company overview
9.4.8.2 Financial performance
9.4.8.3 Product benchmarking
9.4.8.4 Strategic initiatives
LIST OF TABLES
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 North America NSAIDs Market, By Country, 2018 - 2030 (USD Million)
Table 4 North America NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 5 North America NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 6 U.S. NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 7 U.S. NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 8 Canada NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 9 Canada NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 10 Europe NSAIDs Market, By Country, 2018 - 2030 (USD Million)
Table 11 Europe NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 12 Europe NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 13 U.K. NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 14 U.K. NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 15 Germany NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 16 Germany NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 17 France NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 18 France NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 19 Spain NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 20 Spain NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 21 Italy NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 22 Italy NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 23 Asia Pacific NSAIDs Market, By Country, 2018 - 2030 (USD Million)
Table 24 Asia Pacific NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 25 Asia Pacific NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 26 Japan NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 27 Japan NSAIDs Market, By Route of Administration 2018 - 2030 (USD Million)
Table 28 China NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 29 China NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 30 India NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 31 India NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 32 South Korea NSAIDs Market, By Disease Indication 2018 - 2030 (USD Million)
Table 33 South Korea NSAIDs Market, By Route of Administration 2018 - 2030 (USD Million)
Table 34 Australia NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 35 Australia NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 36 Latin America NSAIDs Market, By Country, 2018 - 2030 (USD Million)
Table 37 Latin America NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 38 Latin America NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 39 Brazil NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 40 Brazil NSAIDs Market, By Route of Administration 2018 - 2030 (USD Million)
Table 41 Mexico NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 42 Mexico NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 43 Argentina NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 44 Argentina NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 45 Middle East & Africa NSAIDs Market, By Country, 2018 - 2030 (USD Million)
Table 46 Middle East & Africa NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 47 Middle East & Africa NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 48 South Africa NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 49 South Africa NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 50 Saudi Arabia NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 51 Saudi Arabia NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 52 UAE NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 53 UAE NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 North America NSAIDs Market, By Country, 2018 - 2030 (USD Million)
Table 4 North America NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 5 North America NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 6 U.S. NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 7 U.S. NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 8 Canada NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 9 Canada NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 10 Europe NSAIDs Market, By Country, 2018 - 2030 (USD Million)
Table 11 Europe NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 12 Europe NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 13 U.K. NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 14 U.K. NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 15 Germany NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 16 Germany NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 17 France NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 18 France NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 19 Spain NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 20 Spain NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 21 Italy NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 22 Italy NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 23 Asia Pacific NSAIDs Market, By Country, 2018 - 2030 (USD Million)
Table 24 Asia Pacific NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 25 Asia Pacific NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 26 Japan NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 27 Japan NSAIDs Market, By Route of Administration 2018 - 2030 (USD Million)
Table 28 China NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 29 China NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 30 India NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 31 India NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 32 South Korea NSAIDs Market, By Disease Indication 2018 - 2030 (USD Million)
Table 33 South Korea NSAIDs Market, By Route of Administration 2018 - 2030 (USD Million)
Table 34 Australia NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 35 Australia NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 36 Latin America NSAIDs Market, By Country, 2018 - 2030 (USD Million)
Table 37 Latin America NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 38 Latin America NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 39 Brazil NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 40 Brazil NSAIDs Market, By Route of Administration 2018 - 2030 (USD Million)
Table 41 Mexico NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 42 Mexico NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 43 Argentina NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 44 Argentina NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 45 Middle East & Africa NSAIDs Market, By Country, 2018 - 2030 (USD Million)
Table 46 Middle East & Africa NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 47 Middle East & Africa NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 48 South Africa NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 49 South Africa NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 50 Saudi Arabia NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 51 Saudi Arabia NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 52 UAE NSAIDs Market, By Disease Indication, 2018 - 2030 (USD Million)
Table 53 UAE NSAIDs Market, By Route of Administration, 2018 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 NSAIDs market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 NSAIDs market snapshot
Fig. 10 NSAIDs market driver impact
Fig. 11 NSAIDs market restraint impact
Fig. 12 Penetration and growth prospect mapping
Fig. 13 SWOT analysis, by a factor (political & legal, economic, and technological)
Fig. 14 Porter’s five forces analysis
Fig. 15 Ansoff matrix
Fig. 16 NSAIDs market: Disease indication outlook and key takeaways
Fig. 17 NSAIDs market: Disease indication movement analysis
Fig. 18 Disease indication segment dashboard
Fig. 19 Arthritis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Migraine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Ophthalmic diseases market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Other market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 NSAIDs market: Route of administration outlook and key takeaways
Fig. 24 NSAIDs market: Route of administration movement analysis
Fig. 25 Route of administration segment dashboard
Fig. 26 Oral market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Topical market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Other market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 NSAIDs market: Distribution channel outlook and key takeaways
Fig. 30 NSAIDs market: Distribution channel movement analysis
Fig. 31 Distribution channel segment dashboard
Fig. 32 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 NSAIDs market: regional outlook and key takeaways
Fig. 36 Regional outlook, 2021 & 2030 (USD Million)
Fig. 37 Regional market dashboard
Fig. 38 North America
Fig. 39 North America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 U.S.
Fig. 41 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Canada
Fig. 43 Canada market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Europe
Fig. 45 Europe market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 Germany
Fig. 47 Germany market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 U.K.
Fig. 49 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Spain
Fig. 51 Spain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 France
Fig. 53 France market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 Italy
Fig. 55 Italy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 56 Asia Pacific
Fig. 57 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 58 Japan
Fig. 59 Japan market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 60 China
Fig. 61 China market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 62 India
Fig. 63 India market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 64 South Korea
Fig. 65 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 66 Australia
Fig. 67 Australia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 68 Latin America
Fig. 69 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 70 Brazil
Fig. 71 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 72 Mexico
Fig. 73 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 74 Argentina
Fig. 75 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 76 Middle East & Africa
Fig. 77 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 78 South Africa
Fig. 79 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 80 UAE
Fig. 81 UAE market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 82 Saudi Arabia
Fig. 83 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 84 Participant categorization
Fig. 85 Strategy mapping
Fig. 86 Strategic framework
Fig. 87 Company market share analysis
Fig. 1 NSAIDs market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 NSAIDs market snapshot
Fig. 10 NSAIDs market driver impact
Fig. 11 NSAIDs market restraint impact
Fig. 12 Penetration and growth prospect mapping
Fig. 13 SWOT analysis, by a factor (political & legal, economic, and technological)
Fig. 14 Porter’s five forces analysis
Fig. 15 Ansoff matrix
Fig. 16 NSAIDs market: Disease indication outlook and key takeaways
Fig. 17 NSAIDs market: Disease indication movement analysis
Fig. 18 Disease indication segment dashboard
Fig. 19 Arthritis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Migraine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Ophthalmic diseases market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Other market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 NSAIDs market: Route of administration outlook and key takeaways
Fig. 24 NSAIDs market: Route of administration movement analysis
Fig. 25 Route of administration segment dashboard
Fig. 26 Oral market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Topical market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Other market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 NSAIDs market: Distribution channel outlook and key takeaways
Fig. 30 NSAIDs market: Distribution channel movement analysis
Fig. 31 Distribution channel segment dashboard
Fig. 32 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 NSAIDs market: regional outlook and key takeaways
Fig. 36 Regional outlook, 2021 & 2030 (USD Million)
Fig. 37 Regional market dashboard
Fig. 38 North America
Fig. 39 North America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 U.S.
Fig. 41 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Canada
Fig. 43 Canada market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Europe
Fig. 45 Europe market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 Germany
Fig. 47 Germany market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 U.K.
Fig. 49 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Spain
Fig. 51 Spain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 France
Fig. 53 France market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 Italy
Fig. 55 Italy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 56 Asia Pacific
Fig. 57 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 58 Japan
Fig. 59 Japan market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 60 China
Fig. 61 China market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 62 India
Fig. 63 India market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 64 South Korea
Fig. 65 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 66 Australia
Fig. 67 Australia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 68 Latin America
Fig. 69 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 70 Brazil
Fig. 71 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 72 Mexico
Fig. 73 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 74 Argentina
Fig. 75 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 76 Middle East & Africa
Fig. 77 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 78 South Africa
Fig. 79 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 80 UAE
Fig. 81 UAE market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 82 Saudi Arabia
Fig. 83 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 84 Participant categorization
Fig. 85 Strategy mapping
Fig. 86 Strategic framework
Fig. 87 Company market share analysis
